Related Experiment Video
Updated: Oct 13, 2025

Extraction and Analysis of Taiwanese Green Propolis
Published on: January 7, 2019
Microencapsulated and Lyophilized Propolis Co-Product Extract as Antioxidant Synthetic Replacer on Traditional
Rodrigo Rodrigues1, Denise Bilibio2, Manuel S V Plata-Oviedo3
1Department of Chemistry, Federal Technological University of Paraná (UTFPR), Pato Branco 85503-390, Brazil.
Abstract:
The residue from commercial propolis extraction may have significant antioxidant power in food technology. However, among the challenges for using the propolis co-product as an inhibitor of lipid oxidation (LO) in baked goods is maintaining its bioactive compounds. Therefore, this study aimed to determine the propolis co-product extracts' capability to reduce LO in starch biscuit formulated with canola oil and stored for 45 days at 25 °C. Two co-product extracts were prepared: microencapsulated propolis co-product (MECP) (with maltodextrin) and lyophilized propolis co-product (LFCP), which were subjected to analysis of their total phenolic content and antioxidant activity (AA). Relevant antioxidant activity was observed using the methods of analysis employed. The spray-drying microencapsulation process showed an efficiency of 63%. The LO in the biscuits was determined by the thiobarbituric acid reactive substances (TBARS) test and fatty acid composition by gas chromatography analysis. Palmitic, stearic, oleic, linoelaidic, linoleic, and α-linolenic acids were found in biscuits at constant concentrations throughout the storage period. In addition, there was a reduction in malondialdehyde values with the addition of both propolis co-product extracts. Therefore, the propolis co-product extracts could be utilized as a natural antioxidant to reduce lipid oxidation in fatty starch biscuit.
Related Concept Videos
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Additives and Fillers in Concrete
The...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

